A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients

Document Type : Original Article


1 Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Skin and Stem cell Research Center, Tehran University of Medical Sciences, Tehran, Iran


Background: Vitiligo, a common disorder of depigmentation, is often difficult to treat. Corticosteroids are known to be effective, but with modest results. Although simvastatin has been reported to be effective for immunorelated dermatologic disorders including vitiligo, controlled trials are lacking. This study was conducted to compare the efficacy of topical betamethasone valerate 0.1% cream (as a standard method of treatment for vitiligo) versus a combination of betamethasone valerate plus oral simvastatin in the treatment of vitiligo. Materials and Methods: Eighty-eight subjects with symmetric vitiligo who had body surface involvement up to 20% were divided randomly into two groups. Group A were treated with betamethasone valerate 01% cream twice daily and Group B with betamethasone valerate 01% cream twice daily and oral simvastatin 80 mg daily for 12 weeks. Finally, 46 patients completed treatment after 12 weeks in both groups. The results were evaluated by a blind dermatologist using Vitiligo Area Scoring Index (VASI) score at baseline, 4th, 8th, and 12th week of treatment. In a similar way, subjective assessment performed by patients based on photo evaluation at the end of the study. Results: Despite a continuous reduction in VASI score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo. Conclusion: This study indicates that oral simvastatin is not associated with significant impacts in the treatment of vitiligo as compared to other inflammatory dermatologic conditions such as psoriasis. Indeed, other studies should be initiated regarding exact molecular and cellular effects of statins in the treatment of vitiligo.


Ortonne JP, Passeron T. Vitiligo and other disorders of hypopigmentation. In: Bolognia J, Jorizzo J, Schaffer J, editors. Dermatolog. 3rd ed. Elsevier Saunders; 2012. p. 1023-48.  Back to cited text no. 1
Dwivedi M, Laddha NC, Shajil EM, Shah BJ, Begum R. The ACE gene I/D polymorphism is not associated with generalized vitiligo susceptibility in Gujarat population. Pigment Cell Melanoma Res 2008;21:407-8.  Back to cited text no. 2
Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985;2:71-8.  Back to cited text no. 3
Dogra S, Parsad D, Handa S, Kanwar AJ. Late onset vitiligo: A study of 182 patients. Int J Dermatol 2005;44:193-6.  Back to cited text no. 4
Halder RM, Taliaferro SJ. Vitiligo. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, editors. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill; 2008. p. 72.  Back to cited text no. 5
Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, et al. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-32.  Back to cited text no. 6
Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.  Back to cited text no. 7
Lee AY, Kim NH, Choi WI, Youm YH. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. J Invest Dermatol 2005;124:976-83.  Back to cited text no. 8
Falabella R, Barona MI. Update on skin repigmentation therapies in vitiligo. Pigment Cell Melanoma Res 2009;22:42-65.  Back to cited text no. 9
Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 2002;59:970-1.  Back to cited text no. 10
Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.  Back to cited text no. 11
Dobreanu M, Dobreanu D, Fodor A, Bacarea A. Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med 2007;45:193-9.  Back to cited text no. 12
Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, et al. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 2008;196:601-13.  Back to cited text no. 13
Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: A new therapeutic target in inflammatory dermatoses. J Dermatolog Treat 2008;19:318-26.  Back to cited text no. 14
Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.  Back to cited text no. 15
Namazi MR. Statins: Novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-9.  Back to cited text no. 16
Naseri M, Hadipour A, Sepaskhah M, Namazi MR. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: A double-blind, randomized, placebo-controlled study. Niger J Med 2010;19:58-61.  Back to cited text no. 17
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: The Vitiligo Area Scoring Index. Arch Dermatol 2004;140:677-83.  Back to cited text no. 18
Mythili G, Sarma KL. Design and development of an area estimating system to find the body surface area affected by vitiligo using simulation approach. Int J Adv Res Comput Sci Softw Eng 2012;2:75-81.  Back to cited text no. 19
Fai D, Cassano N, Vena GA. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: A review of 110 patients. J Eur Acad Dermatol Venereol 2007;21:916-20.  Back to cited text no. 20
Hann SK, Park YK. New concepts in vitiligo. Clin Dermatol 1997;15:835-41.  Back to cited text no. 21
Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001;131:41-6.  Back to cited text no. 22
Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006;20:269-73.  Back to cited text no. 23
Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984;120:631-5.  Back to cited text no. 24
Shahmoradi S, Mokhtari F, Faghihi G, Adibi N. Comparing the efficacy of topical clobetasol 0.05% plus 5-fluorouracil 5% cream vs. topical clobetasol 0.05% alone in treatment of vitiligo. J Res Med Sci 2012;17:17-23.  Back to cited text no. 25
Wolkenstein P, Revuz J, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S, et al. Psoriasis in France and associated risk factors: Results of a case-control study based on a large community survey. Dermatology 2009;218:103-9.  Back to cited text no. 26
Noël M, Gagné C, Bergeron J, Jobin J, Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis 2004;3:7.  Back to cited text no. 27